RESULTS OF ADJUVANT CHEMOTHERAPY IN STAGE II-III COLON CANCER PATIENTS USING THE mFOLFOX6 REGIMEN AT BAC NINH CANCER HOSPITAL
Main Article Content
Abstract
Objective: To describe the clinical and paraclinical characteristics and evaluate treatment outcomes in patients with stage II–III colon cancer receiving adjuvant chemotherapy with the mFOLFOX6 regimen at Bac Ninh Cancer Hospital.
Subjects and Methods: A retrospective descriptive study was conducted on 55 patients with stage II–III colon cancer who received adjuvant chemotherapy with the mFOLFOX6 regimen at Bac Ninh Cancer Hospital from January 2020 to January 2025. The evaluated variables included clinical and paraclinical characteristics, disease stage, number of harvested lymph nodes, overall survival, disease-free survival, and treatment-related toxicities.
Results: The mean age was 59.9 ± 9.2 years. Abdominal pain was the most common reason for hospital admission, accounting for 70.9% of cases. Right-sided colon tumors accounted for 58.2% and left-sided tumors for 41.8%; adenocarcinoma was the most common histological type, accounting for 81.8%. High-risk stage II and stage III disease accounted for 54.5% and 45.5%, respectively. Fewer than 12 lymph nodes were harvested in 29.1% of patients. The mean follow-up duration was 35.8 ± 12.3 months. The 3-year overall survival and disease-free survival rates were 88.7% and 78.3%, respectively. Most toxicities were grade 1–2, while grade 3–4 toxicities were primarily hematologic.
Conclusion: The mFOLFOX6 regimen showed favorable survival outcomes and relatively good tolerability in patients with high-risk stage II and stage III colon cancer.
Keywords
mFOLFOX6, adjuvant treatment, colon cancer, stage II–III, toxicity
Article Details
References
2. Trần Thị Ngọc Ánh, Ngô Thị Tính, and Trần Thị Kim Phượng, “Kết quả hóa trị bổ trợ phác đồ mFOLFOX6 ở bệnh nhân ung thư đại tràng tại Bệnh viện Trung ương Thái Nguyên,” (in V), Tạp chí khoa học công nghệ Đại học Thái Nguyên (TNU Journal of Science Technology), vol. 230, no. 05, pp. 85-92, 2025.
3. A. D. Roth et al., “Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer,” (in English), J Natl Cancer Inst, vol. 104, no. 21, pp. 1635-46, Nov 7 2012.
4. Y. Kim, M. K. Kim, and S. J. A. J. o. C. R. Lee, “A comparative genomic analysis of left-and right-sided colon cancer using real-world data from the AACR project GENIE BPC dataset,” (in English), vol. 15, no. 9, p. 4182, 2025.
5. Y. Zhang et al., “A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites,” (in English), vol. 30, no. 9, pp. 1173-1183, 2015.
6. T. Andre et al., “Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study,” (in English), J Clin Oncol, vol. 33, no. 35, pp. 4176-87, Dec 10 2015.
7. Lê Bá Tuấn Anh và cộng sự, “Results of modified folfox6 as adjuvant chemotherapy in high-risk stage II and III colon cancer at Thanh Hoa oncology hospital,” Vietnam Medical Journal, vol. 536, no. 1, 03/04 2024.
8. T. Q. Nguyen et al., “Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer,” (in English), Cancer Control, vol. 26, no. 1, p. 1073274819864111, Jan-Dec 20 19.
9. H. Minh Cuong, V. Hong Thang, B.-T. Thu Huong, N. Thuan Loi, and N. Minh Duc, “KRAS mutations and their associations with clinicopathological features and survival in Vietnamese non‑polyp colon cancer patients,” Mol Clin Oncol, vol. 19, no. 2, p. 63, 2023/08/01 2023.